qsc retatrutide Phase 3: 60% Achieved Surgical-Level Weight Loss Unapproved weight-loss drug "reta" sold

These medications slow stomach emptying, which can increase the risk of aspiration during anesthesia

Tell your healthcare provider if you are taking medicines to treat diabetes including insulin or sulfonylureas which could increase your risk of low blood sugar

Coverage is available if you meet strict requirements: BMI 30 (or 27 with comorbidity), failed 2+ other weight loss medications, AND tried semaglutide for at least 6 months

Thats according to a small clinical trial run by Novo Nordisk, so real-life results may vary

Free consultation Benefits Triple mechanism of action only GLP-1 + GIP + glucagon agonist 12 mg optimal pen for escalation phase (26 mg/week) Pre-Mixed stabilized pen ready solution, no reconstitution needed MSSPT technology tolerant to short-term temperature fluctuations Purity 98% GMP-certified manufacturing in Europe Up to 24% weight loss over 48 weeks (Phase 2 study, NEJM 2023) Cold chain delivery in thermoboxes with cooling elements (28C) across Ukraine Free 24/7 DOZA specialist support throughout the entire course Retatrutide 12 mg (PEN PEPTIDE) detailed description Retatrutide 12 mg from PEN PEPTIDE triple agonist of GLP-1, GIP and glucagon receptors in a stabilized pen